AND EXCHANGE COMMISSION
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
of report (Date of earliest event reported): November 21, 2018
name of registrant as specified in its charter)
or other jurisdiction
Avenue of the Stars, 2nd Floor
of principal executive offices)
telephone number, including area code: (530) 231-7800|
name or former address, if changed since last report.)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
growth company [ ]
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
November 21, 2018, Vitality Biopharma, Inc. (the “Company”) issued a press release providing a corporate update
to the Company’s investors and announcing the termination of the previously disclosed Section 8(e) examination relating
to a registration statement filed by the Company in 2016.
foregoing description of the press release does not purport to be complete and is qualified in its entirety by reference to the
full text of the document. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is
incorporated herein by reference.
information set forth under Item 8.01 of this Current Report on Form 8-K is furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, and shall not be deemed incorporated by reference in any filing with the Securities and Exchange
Commission under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference
in such filing.
of this Current Report on Form 8-K may constitute “forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995 that are subject to risks and uncertainties. Although the Company believes any such statements are
based on reasonable assumptions, there is no assurance that the actual outcomes will not be materially different due to a number
of factors. Any such statements are made in reliance on the “safe harbor” protections provided under the Private Securities
Litigation Reform Act of 1995. Additional information about significant risks that may impact the Company is contained in the
Company’s filings with the Securities and Exchange Commission and may be accessed at www.sec.gov. The Company is under no
obligation, and expressly disclaims any obligation, to update or alter its forward-looking statements, whether as a result of
new information, future events or otherwise.
Statements and Exhibits.|
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
||VITALITY BIOPHARMA, INC.|
|Dated: November 21, 2018
||/s/ Robert Brooke|
||Chief Executive Officer|